About The Study: In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety. Lysergide, or lysergic acid diethylamide (LSD), is a semisynthetic psychedelic drug. An oral pharmaceutical formulation of LSD is MM120. These results support the dose-dependent efficacy of MM120 and inform the dose selection for phase 3 pivotal trials.
Corresponding Author: To contact the corresponding author, Daniel R. Karlin, MD, MA, email medaffairs@mindmed.co .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.13481)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.13481?guestAccessKey=f420494d-a51d-442c-9d7c-4d14dbbe1aae&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090425
JAMA